Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

Di Bartolomeo, M

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. [electronic resource] - Targeted oncology Jun 2014 - 155-62 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

1776-260X

10.1007/s11523-013-0283-8 doi


Adenocarcinoma--drug therapy
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Biomarkers, Tumor--genetics
Cetuximab
Colorectal Neoplasms--drug therapy
DNA Mutational Analysis
Disease-Free Survival
Drug Resistance, Neoplasm--genetics
Female
GTP Phosphohydrolases--genetics
Humans
Kaplan-Meier Estimate
Male
Membrane Proteins--genetics
Mutation
Nuclear Proteins--genetics
Organoplatinum Compounds--administration & dosage
Oxaliplatin
Proto-Oncogene Proteins--genetics
Proto-Oncogene Proteins B-raf--genetics
Proto-Oncogene Proteins p21(ras)
Reverse Transcriptase Polymerase Chain Reaction
Tegafur--administration & dosage
Transcription Factors--genetics
Tumor Suppressor Protein p53--genetics
Uracil--administration & dosage
ras Proteins--genetics